New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
10:01 EDTRAX, LEJU, GLRI, EBS, PBCT, ICPT, GSK, CHKE, SUSQ, MPET, ITW, FCF, CAMP, BDSI, ACADOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ACADIA (ACAD) initiated with an Overweight at JPMorgan... BioDelivery Sciences (BDSI) initiated with a Buy at Summer Street... CalAmp (CAMP) initiated with an Overweight at Stephens... Cherokee (CHKE) initiated with a Buy at B. Riley... Emergent BioSolutions (EBS) initiated with a Buy at Summer Street... First Commonwealth (FCF) initiated with a Neutral at SunTrust... GlaxoSmithKline (GSK) initiated with an Overweight at JPMorgan... Glori Energy (GLRI) initiated with a Buy at Maxim... Illinois Tool Works (ITW) reinstated with a Neutral at Credit Suisse... Intercept (ICPT) initiated with a Buy at Summer Street... Leju (LEJU) initiated with an Outperform at Macquarie... Magellan Petroleum (MPET) initiated with a Buy at B. Riley... People's United (PBCT) initiated with a Neutral at SunTrust... Rackspace (RAX) assumed with an Overweight at JPMorgan... Susquehanna (SUSQ) initiated with a Neutral at SunTrust.
News For ACAD;BDSI;CAMP;CHKE;EBS;FCF;GSK;GLRI;ITW;ICPT;LEJU;MPET;PBCT;RAX;SUSQ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 3, 2015
07:04 EDTACADACADIA submits NDA for Nuplazid for treatment of Parkinson's Disease psychosis
Subscribe for More Information
07:04 EDTACADACADIA names Steve Davis president, CEO
ACADIA Pharmaceuticals announced that its Board of Directors has appointed Steve Davis as President and CEO. Davis has been serving as ACADIA's Interim Chief Executive Officer since March 2015. Davis has also been appointed to the ACADIA Board of Directors.
06:54 EDTITWIllinois Tool Works upgraded to Buy from Neutral at Goldman
Goldman upgraded Illinois Tool Works to Buy and lowered its price target to $99 from $101. The firm views Illinois Tool Works' valuation as compelling and earnings will be more resilient than investors believe. Goldman believes the company's margin story still has room to expand driven by improved sourcing, amortization roll-off, product line simplification, and cost efficiencies.
September 2, 2015
12:46 EDTGSKGlaxoSmithKline reports 24.5% passive stake in Theravance Biopharma
Subscribe for More Information
07:56 EDTCHKECherokee weakness a buying opportunity, says Brean Capital
Subscribe for More Information
September 1, 2015
07:34 EDTGSKAdaptimmune expands trial of T-cell therapy for synovial sarcoma
Adaptimmune Therapeutics (ADAP) announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients. Based on encouraging results in the first cohort of 10 patients, presented at the American Association for Cancer Research annual meeting in April 2015, the trial is being expanded to encompass an additional 20 patients in two further cohorts. The expansion of Adaptimmune's trial also triggers two milestone payments from GlaxoSmithKline (GSK). Adaptimmune is collaborating with GSK for the development of its NY-ESO TCR program through a strategic cancer immunotherapy partnership announced in June 2014. Under the terms of the agreement, GSK has an exclusive option to license Adaptimmune's NY-ESO TCR therapeutic and upon exercise would assume full responsibility for further development and commercialization of the therapeutic. Adaptimmune's clinical study includes synovial sarcoma patients who have received standard first line therapy containing ifosfamide and/or doxorubicin and who are intolerant or no longer responding to the regimen, and whose tumor expresses a tumor antigen known as NY-ESO-1. The NY-ESO-1 antigen is believed to be present in 60 to 70 percent of synovial sarcoma patients.The primary objectives of the study are to determine the safety of adoptively transferred autologous T cells expressing an affinity enhanced T cell receptor that recognizes the NY-ESO-1 antigen in HLA-A*0201, HLA-A*0205, and/or HLA-A*0206 positive patients with unresectable, metastatic or recurrent synovial sarcoma. Secondary objectives include the determination of efficacy through response rate and duration of response.
August 31, 2015
07:11 EDTICPTIntercept announces NDA for OCA accepted for review by FDA
Subscribe for More Information
August 27, 2015
10:00 EDTACADOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:57 EDTCAMPCalAmp management to meet with B. Riley
Subscribe for More Information
06:37 EDTACADACADIA upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
August 26, 2015
17:06 EDTGSKGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
09:07 EDTCHKECherokee enters into license agreement with 5 Horizons for Everyday California
Subscribe for More Information
August 25, 2015
09:59 EDTACADOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:07 EDTACADACADIA initiated with a Buy at Aegis
Subscribe for More Information
05:37 EDTLEJULeju sees FY15 revenue $600M-$620M, consensus $617.53M
Subscribe for More Information
05:37 EDTLEJULeju reports Q2 EPS 12c, consensus 11c
Subscribe for More Information
August 24, 2015
13:15 EDTGSKFDA expands use of Novartis' Promacta to include children ages 1 and older
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
August 21, 2015
16:38 EDTACADACADIA unit manufacturing agreement with BASF Pharma
On August 17, our Swiss subsidiary, ACADIA Pharmaceuticals GmbH, entered into a co-operation agreement and product schedule, collectively referred to as the manufacturing agreement, with BASF Pharma SA, or BASF. Under the manufacturing agreement, BASF has agreed to manufacture and supply pimavanserin tartrate, the active pharmaceutical ingredient of NUPLAZID, for commercial use. The term of the manufacturing agreement extends through December 31, 2020 and will automatically renew for subsequent one year terms unless either party provides timely notice of its intent not to renew, or unless the manufacturing agreement is terminated earlier pursuant to its terms.
05:25 EDTGSKNovartis acquires all remaining rights to Ofatumumab from GSK
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
August 20, 2015
09:09 EDTCAMPCalAmp announces OEM partnership with Toyota
CalAmp has signed an OEM partner agreement to provide devices and platform services to power Toyota Industrial Equipment's, or TIE, new T-Matics MOBILE Vehicle Management System, or VMS, a fleet management tool that tracks and reports operating behavior of forklifts and forklift operators communicating over public cellular networks. The CalAmp solution will be installed directly on TIE's production line.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use